GlassScriptPhysician profile
Kerry L Hendershot
NPI 1700849544
$5,939.21
in general payments reported to CMS, 2019-2025
52 companies · $954 in 2025
The $954 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $532 · 2021: $1,249 · 2022: $887 · 2023: $988 · 2024: $384 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.82 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.74 | 2021-2025 | |
| Novo Nordisk INC | $607.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $492.11 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $407.54 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $366.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $290.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $260.26 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.65 | 2019-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $176.34 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $148.54 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $139.61 | 2025 | Gemtesa |
| Amgen INC. | $130.08 | 2019-2024 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $126.88 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $124.02 | 2019-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $120.01 | 2019-2025 | Verquvo |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Hendershot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.